Credit:
Photo Illustration by Andrea Wise/ProPublica. Source images: luza studios/Getty Images, MirageC/Getty Images, Farion_O/Getty Images.
Health Care
Seven Things to Know About ProPublica’s Investigation of the FDA’s Secret Gamble on Generic Drugs
ProPublica spent 14 months investigating the FDA’s oversight of foreign drugmakers that send medications to the U.S. These are the key takeaways.
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published.
In 2022, three Food and Drug Administration inspectors headed to India to investigate a massive Sun Pharma plant that produces dozens of generic drugs for Americans. Over two weeks, they found dangerous breakdowns in the way critical medications were made, and the FDA ultimately placed the factory on an import ban — prohibiting the company from shipping drugs to the United States.
The agency, however, quietly gave the global manufacturer a special pass to continue sending more than a dozen drugs to Americans even though they were made at the same substandard factory that was officially banned from the U.S. market.
It wasn’t the first time. Here are the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers:
- Over a dozen years, the agency entrusted to protect America’s drug supply gave similar exemptions to some of the most troubled foreign drugmakers in India, allowing factories banned from the U.S. market to continue shipping medications to an unsuspecting American public.
- A secretive group inside the FDA exempted the medications from import bans, ostensibly to prevent drug shortages. With each pass, the agency dismissed warnings from its own inspectors about dangerous breaches in drug quality on factory floors. All told, the FDA allowed into the United States at least 150 drugs or their ingredients from banned factories found to have mold, foul water, dirty labs or fraudulent testing protocols. Nearly all came from factories in India.
- The FDA did not regularly test the drugs exempted from import bans to see if they were safe or actively monitor reports about potential harm among patients. And as the drugs circulated in the United States, the agency kept the practice largely hidden from the public. The FDA said it put protective measures in place, such as requiring third-party oversight of factories to ensure the exempted drugs were safe.
- Some of the exempted drugs were recalled — just before or just after they were exempted — because of contaminants or other defects that could cause health problems. And a ProPublica analysis identified more than 600 complaints in the FDA’s files about the exempted drugs at three factories alone, each flagging concerns in the months or years after the medications were excluded from import bans. The reports cite about 70 hospitalizations and nine deaths.
- Janet Woodcock, who for more than two decades led the FDA’s Center for Drug Evaluation and Research, said she didn’t see a need to inform the public about the drugs from banned factories because the agency believed they were safe and that such information would create “some kind of frenzy” among consumers who might seek to change their prescriptions. “We had to kind of deal with the hand we were dealt,” she said, noting she supported the exemptions to deal with chronic drug shortages.
- Decisions made by the FDA decades ago gave rise to the use of exemptions. In the 2000s, as the cost of brand-name drugs soared, the FDA approved hundreds of generic drug applications for foreign manufacturers that had been in trouble before, companies well-known to the inspectors working to stamp out safety and quality breakdowns.
- The exempted drugs that have come to the United States include antibiotics, chemotherapy treatment, antidepressants, sedatives and epilepsy medication.
Sun Pharma did not respond to multiple requests for comment. When the FDA imposed the ban, the company said it would “undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the company’s remedial action. Sun Pharma remains committed to being … compliant and in supplying high-quality products to its customers and patients globally.”
Patricia Callahan and Vidya Krishnan contributed reporting. Alice Crites contributed research.
What We’re Watching
During Donald Trump’s second presidency, ProPublica will focus on the areas most in need of scrutiny. Here are some of the issues our reporters will be watching — and how to get in touch with them securely.
More in Health Care
His Kidney Failed. He’ll Never Know if a Transplant Drug From a Banned Factory Was to Blame.
When Joe DeMayo’s donated kidney started to fail earlier than expected, he didn’t know that the drug he was taking could’ve left him vulnerable — and that one of the most formidable drug regulators in the world may have failed to protect him.
by Debbie Cenziper and Megan Rose,
ProPublica Sued the FDA for Withholding Records About the Safety of Generic Drugs
The agency declined to quickly release documents that would identify drugs made at some of the most troubled foreign factories. The request was part of ProPublica’s ongoing investigation into the safety of America’s generic drug supply.
by Katherine Dailey and Jessie Nguyen, Medill Investigative Lab,
Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs
A ProPublica investigation found that for more than a decade, the FDA gave substandard factories banned from the United States a special pass to keep sending drugs to an unsuspecting public.
by Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang,
We Spent a Year Investigating How the FDA Let Risky Drugs Into the U.S. Market
Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into the U.S. over the past dozen years even though they were made at factories banned from shipping their products here.
by Brandon Roberts, Debbie Cenziper, Megan Rose and Irena Hwang,
Shattered Science: The Research Lost as Trump Targets NIH Funding
The Trump administration cut research funding that sought cures for future pandemics, examined the causes of dementia and tried to prevent HIV transmission. ProPublica heard from more than 150 researchers to understand the work that’s been lost.
by Annie Waldman, Asia Fields and Ashley Clarke, design by Zisiga Mukulu, and photography by Bethany Mollenkof for ProPublica,
Broken Pathways
He Became the Face of Georgia’s Medicaid Work Requirement. Now He’s Fed Up With It.
A 54-year-old mechanic called Pathways to Coverage a “great program” at the governor’s press conference. But after getting kicked off the health insurance program for low-income Georgians twice, bureaucratic red tape has him at his wit’s end.
by Margaret Coker, The Current,
Local Reporting Network
Most Read
“The Intern in Charge”: Meet the 22-Year-Old Trump’s Team Picked to Lead Terrorism Prevention
One year out of college and with no apparent national security expertise, Thomas Fugate is the Department of Homeland Security official tasked with overseeing the government’s main hub for combating violent extremism.
by Hannah Allam,
Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs
A ProPublica investigation found that for more than a decade, the FDA gave substandard factories banned from the United States a special pass to keep sending drugs to an unsuspecting public.
by Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang,
His Kidney Failed. He’ll Never Know if a Transplant Drug From a Banned Factory Was to Blame.
When Joe DeMayo’s donated kidney started to fail earlier than expected, he didn’t know that the drug he was taking could’ve left him vulnerable — and that one of the most formidable drug regulators in the world may have failed to protect him.
by Debbie Cenziper and Megan Rose,
Red State Voters Approved Progressive Measures. GOP Lawmakers Are Trying to Undermine Them.
In the wake of ballot measures that increased abortion access and improved sick leave for workers, a coordinated effort is unfolding across the country to restrict direct democracy — and shift power to partisan legislatures.
by Jeremy Kohler,
What Exactly Is the War Powers Act and Is Obama Really Violating It?
The Obama administration is certainly sidestepping the controversial law known as the War Powers Act, but in doing so he’s following a well-worn path.
by Marian Wang,